Technology | July 29, 2013

Boston Scientific Launches OptiCross Coronary Imaging Catheter in United States, Europe and Japan

OptiCross Boston Scientific Cath Lab IVUS

July 29, 2013 — The Boston Scientific Corporation has received U.S. Food and Drug Administration (FDA) clearance, CE mark and Japan PMDA approval for its OptiCross Coronary Imaging Catheter and has launched the device in the United States and Europe. A launch in Japan is planned for later this month. OptiCross, a next generation intravascular ultrasound (IVUS) catheter, offers better deliverability and higher resolution imaging to facilitate complex coronary procedures.

Designed to be compatible with the Boston Scientific iLab Ultrasound Imaging System, the OptiCross catheter was created with the input of physicians from around the world to reduce the inherent challenges surrounding catheter delivery in complex cases. The upgraded, low profile delivery system features 5 French guide catheter compatibility, a shorter, tapered tip, a bi-segmented catheter shaft and a redesigned catheter hub for ease of connection.

Interventional cardiologists use IVUS to see inside coronary arteries and to gain additional information in order to optimize treatment decisions.

"The OptiCross catheter widens the applicability of ultrasound with the ability to assess disease pre-procedure, without concern regarding ischemia and lesion trauma," said Dr. Neal Uren, clinical director for cardiac services at the Edinburgh Heart Centre, Royal Infirmary, Edinburgh. "The incremental increase in deliverability widens the use of IVUS into more difficult lesion subsets, while maintaining superior image quality."

The benefits of IVUS-guided percutaneous coronary intervention (PCI) were reinforced at TCT 2012 and at EuroPCR in May with the presentation of the ADAPT-DES IVUS sub-study outcomes. The results showed that IVUS can help improve patient outcomes and change the way physicians approach their cases.

For more information: www.bostonscientific.com

Related Content

News | Cath Lab | February 23, 2018
February 23, 2018 — CorFlow Therapeutics AG announced that the company will present new insights into the coronary mi
Teleflex Launches Next-Generation Sympro Elite and Expro Elite Snares
Technology | Cath Lab | February 07, 2018
Teleflex Inc. has announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) and U.S. commercial launch...
SCAI Advocacy Committee Highlights Reimbursement Reform Efforts in 2017
News | Cath Lab | January 30, 2018
The Society for Cardiovascular Angiography and Interventions (SCAI) highlighted the efforts of its Advocacy Committee...
IAC Releases Cardiovascular Catheterization Accreditation Program
News | Cath Lab | January 25, 2018
January 25, 2018 – The Intersocietal Accreditation Commission (IAC) announced the release of its Cardiovascular Cathe
Videos | Cath Lab | January 04, 2018
Bernadette Speiser, BSN, MSN, CCRN, RCIS, a cardiac cath/EP nurse at Palo Alto Veterans Hospital, Palo Alto, Calif.,
FDA Initiates Class I Recall of Sterilmed Reprocessed Agilis Steerable Introducer Sheath
News | Cath Lab | January 04, 2018
The U.S. Food and Drug Administration (FDA) announced a Class I recall of Sterilmed’s Agilis Steerable Introducer...
The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. Athar Ansari, M.D.

The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA system. 

Feature | Cath Lab | November 24, 2017 | Athar Ansari, M.D., FACC
As debates about the current state and future of healthcare rage in Congress, the media and healthcare settings acros
Videos | Cath Lab | November 08, 2017
Juan Granada, M.D., Cardiovascular Research Foundation president and chief executive officer, shares his insights on
Results of the ORBITA study found no difference in exercise time after six weeks in patients with stable angina who received percutaneous coronary intervention (PCI) versus a placebo treatment. TCT 2017
Feature | Cath Lab | November 06, 2017
November 6, 2017 – Results from ORBITA, a prospective multi-center randomized blinded placebo-controlled study, found
Overlay Init